Bacteria block transmission of Zika and Dengue viruses
Scientists at the University of Glasgow have found a bacterial strain which blocks dengue and Zika virus transmission from mosquitoes.
Symbolic picture
Wikimages; pixabay.com; CC0
In the new study scientists show that a novel strain of the inherited bacteria Wolbachia strongly blocks transmission of dengue and Zika virus among infected mosquitoes, offering a potential alternative to strains already being tested as virus control tools.
Scientists from the University of Glasgow’s MRC Centre for Virus Research (CVR) have carried out the research in the mosquito species Aedes aegypti, which spreads a number of dangerous human viruses, including dengue, Zika, and Chikungunya.
Previous research has shown that transmission of these viruses among mosquitoes is inhibited if the flies are deliberately infected with one strain of Wolbachia bacteria, and several countries are testing whether infecting local mosquito populations with Wolbachia could lower rates of viral disease in humans.
Now University of Glasgow CVR scientists have shown that a novel strain ‘wAu’ is even more effective for virus transmission blocking than strains currently being used, particularly in hot, tropical climates where there is high prevalence of these diseases.
Several Wolbachia strains have already been tested in the field, but there is evidence to suggest that some strains may not block transmission very effectively or may not be inherited efficiently at high ambient temperatures. In the new study, the research team performed laboratory experiments to test the potential promise of alternative Wolbachia strains.
The researchers introduced four Wolbachia strains into Aedes aegypti mosquitoes, which do not naturally carry these arthropod-infecting bacteria. Two of the strains, wMel and wAlbB had already been evaluated in prior studies, and the scientists wanted to compare their effects with those of two novel strains, wAu and wAlbA.
The analysis revealed particularly promising results for strain wAu. After feeding on blood infected with dengue or Zika virus, mosquitoes infected with wAu had lower levels of viral RNA in their body tissue than did mosquitoes infected with the other strains. wAu also showed very high rates of inheritance, including under high-temperature conditions.
Quote from Professor Steven Sinkins: “The Wolbachia transmission blocking strategy shows great promise for the control of mosquito-borne viruses, and is now starting to be deployed on a large scale in a number of tropical countries. Our results with the wAu strain showed by far the effective transmission blocking for all the viruses we tested, and it provides an exciting new option to explore for disease control programmes".
Future research could explore strategies to maximize the effectiveness of wAu in the field, such as combining it with a second strain to help it spread throughout local mosquito populations.
Prof Sinkins holds a Global Challenges Research Fund (GCRF) grant, which is jointly awarded by the Biotechnology and Biological Sciences- and Medical Research Councils (BBSRC and MRC) . With the funding, he will lead a global network studying vector-borne diseases, such as malaria, Dengue and Zika. The goal is to reduce and block the transmission of pathogens by releasing specific insect disease vectors. Wolbachia, for example, is already starting to be deployed in several countries.
Dr Jonathan Pearce, Head of Infections and Immunity at the MRC, said: “This is incredibly relevant research with implications that can be applied to pressing issues on the ground in many parts of the world. These findings may be key to uncovering a new tool in the fight against the spread of mosquito-borne diseases.
“Meanwhile, the international network is pulling together experts from a wide range of scientific disciplines to exchange knowledge and brainstorm promising new ways to target vector-borne diseases.”
Original publication
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
